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Background: Obstructive sleep apnea (OSA) and hypertension are well-known cardiovascular risk factors. Their control
could reduce the burden of heart disease across populations. Several drugs are used to control hypertension, but the
only consistently effective treatment of OSA is continuous positive airway pressure. The identification of a drug capable
of improving OSA and hypertension simultaneously would provide a novel approach in the treatment of both diseases.
Methods/Design: This is a randomized double-blind clinical trial, comparing the use of chlorthalidone with amiloride
versus amlodipine as a first drug option in patients older than 40 years of age with stage I hypertension (140 to 159/90
to 99 mmHg) and moderate OSA (15 to 30 apneas/hour of sleep). The primary outcomes are the variation of the
number of apneas per hour and blood pressure measured by ambulatory blood pressure monitoring. The secondary
outcomes are adverse events, somnolence scale (Epworth), ventilatory parameters and C reactive protein levels. The
follow-up will last 8 weeks. There will be 29 participants per group. The project has been approved by the ethics
committee of our institution.
Discussion: The role of fluid retention in OSA has been known for several decades. The use of diuretics are well
established in treating hypertension but have never been appropriately tested for sleep apnea. As well as testing the
efficacy of these drugs, this study will help to understand the mechanisms that link hypertension and sleep apnea and
their treatment.
Trial registration: ClinicalTrials.gov: NCT01896661
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Obstructive sleep apnea (OSA) is a well-known cardiovas-
cular risk factor and a major cause of secondary hyperten-
sion [1,2]. About 30% of the population suffers from OSA
and it is moderate to severe (more than 15 apneas/hour of
sleep) in 16.9% of adults [3]. OSA is observed in 30% to
80% of hypertensive patients [4]. We demonstrated that
38% of patients with controlled hypertension have OSA, in
contrast to 71% of patients with resistant hypertension [5].
Each episode of apnea/hour increases the risk of hyperten-
sion by 4% [6].
The association between OSA and hypertension has
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reproduction in any medium, provided the orof hypertension [7]. The high cost and low availability of
the golden standard method for diagnosing OSA, full
polysomnography, may be one of the reasons [8,9]. The
use of portable devices, which have been validated in
our laboratory, could circumvent this limitation, since
they have reasonable sensitivity (96%) and specificity
(64%) [10].
The standard treatment for OSA is continuous positive
airway pressure (CPAP) and 46 clinical trials show the
benefits [11]. It has also been shown in randomized clin-
ical trials that CPAP lowers blood pressure, particularly
in patients with hypertension [12]. Blood pressure de-
creased by 7.8/5.3 mmHg in the 24 h ambulatory blood
pressure monitoring in patients with OSA and hyperten-
sion, but did not decrease in those without OSA [13].
The efficacy of CPAP in patients with milder forms of
OSA is still unproven [14], which could be secondary toral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apies could be beneficial in such patients [15].
A Cochrane review, which identified 26 clinical trials
of 21 drugs totaling 394 patients, failed to identify any
pharmacological treatment with consistent efficacy. Some
drugs, like fluticasone, mirtazapine, physostigmine and
nasal lubricants, seem to reduce the number of apneas, but
the trials were small and had methodological limitations,
precluding the use of these drugs in clinical practice [15].
It has been suggested that drug therapy must be tailored to
the mechanism of OSA identified in each patient [15].
An extravascular fluid shift has been implicated in the
physiopathology of OSA. During the night, a shift of
fluids from the legs causes an increase in neck circum-
ference, peripharyngeal pressure and upper airway col-
lapsibility [16-19]. Almost 60 years ago an increase of
0.5 cm in the size of the earlobes during sleep was de-
scribed [20]. The application of lower body pressure of
40 mmHg using antishock trousers reduces leg fluid vol-
ume and increases neck circumference and the resist-
ance of the pharynx [18].
Patients with controlled hypertension underwent a re-
duction of 175 mL in leg volume and an increase of
1.0 cm in neck circumference after sleeping, in compari-
son with a leg volume reduction of 346.7 mL and an in-
crease in the neck circumference of 1.5 cm in patients
with resistant hypertension [21]. The leg volume shift is
positively correlated to the number of apneas (R2 = 0.56)
[21]. CPAP reduced the increase in neck size propor-
tional to the reduction in the number of apneas, but it
did not prevent the leg volume change [19].
Sympathetic renal ablation with radio-frequency waves
reduced blood pressure by 33/11 mmHg in 6 months
[22]. It also reduced the number of apneas/hour from
16.3 to 4.5 for ten patients with resistant hypertension
and OSA [23], an effect that was attributed to the pro-
motion of salt excretion and total body fluid reduction
[23]. Spironolactone led to a reduction from 39.8 to 22.0
apneas/hour after 8 weeks of treatment of 12 patients
with resistant hypertension [24]. There is no controlled
study exploring the concept that these drugs may act
through total body fluid reduction.
In the ALLHAT trial, chlorthalidone, lisinopril and amlo-
dipine had comparable efficacy in the prevention of coron-
ary heart disease [25]. The diuretic, however, was superior
to lisinopril in the prevention of strokes and amlodipine in
the prevention of heart failure [25]. There is evidence that
the efficacy in the prevention of events is related to the
magnitude of the blood pressure reduction [25,26].
The main adverse event for chlorthalidone is hypo-
kalemia, which blunted the efficacy of the treatment in
the SHEP trial [27] and increased serum glucose levels [28].
The use of amiloride, a physiological aldosterone antagon-
ist, could ameliorate this adverse effect. This potassium-sparing diuretic was effective and well tolerated in a ran-
domized trial performed by our group [29].
Amlodipine was more effective than valsartan, an angio-
tensin receptor blocker, in the prevention of myocardial
infarction and stroke in the VALUE trial [30]. In the AC-
COMPLISH trial, the combination benazepril-amlodipine
was more effective in the prevention of composite car-
diovascular events than the combination benazepril-
hydrochlorothiazide [31]. There is no evidence that
amlodipine influences the balance of fluids, and edema
is one of its main adverse effects.
Overall the evidence shows that chlorthalidone and
amlodipine are the most effective drugs for the initial
treatment of hypertension. Their use in OSA has not been
appropriately tested to date. Thus, a trial testing the effi-
cacy of these drugs to control both blood pressure and
sleep apnea is warranted. Such a trial could contribute to
our understanding of the relation between hypertension,
fluid levels, hypoxia and OSA.
Rationale
OSA has been associated with fluid retention, which ac-
cumulates in the pharynx facilitating its collapse, gener-
ating intermittent hypoxia and increasing sympathetic
activity and blood pressure. CPAP alleviates apnea, which
reduces sympathetic activity, reducing blood pressure and
increasing salt and water excretion. Sympathetic renal ab-
lation promotes salt and water excretion, reducing sys-
temic sympathetic activity and total body water (including
the pharynx), thus alleviating apnea. Diuretics could be a
new way to abort this vicious cycle by promoting the dir-
ect excretion of salt and water.
Research question
Is chlorthalidone with amiloride effective in the treat-
ment of OSA in comparison to amlodipine in patients
with OSA and hypertension?
Methods/design
This is a randomized double-blind clinical trial, controlled
by an active treatment.
Eligible participants
Eligible participants are patients older than 40 years of age
with stage I hypertension (140 to 159/90 to 99 mmHg)
and moderate OSA (15 to 30 apneas/hour of sleep).
Exclusion criteria
Patients are excluded if they have a low life expectancy,
other indications for the use of diuretics or calcium chan-
nel blockers, intolerance or contraindications to the study
drugs, cardiovascular disease (heart failure or recent –
within three months – myocardial infarction or stroke),
secondary hypertension or participated in another clinical
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use more than one drug for hypertension.Random allocation
Randomization will be done using a list generated by
validated software (a random allocator), with a block size
of four.Interventions
The interventions are chlorthalidone plus amiloride 25 mg
and 5 mg daily, respectively, versus amlodipine 10 mg daily,
taken in the morning.Outcomes
Primary outcomes
1. Number of apneas/hour (apnea-hypopnea index)
2. Blood pressureSecondary outcomes
1. Adverse events
2. Somnolence scale (Epworth)
3. Respiratory parameters
4. C reactive proteinFollow-up and duration of the study
There will be outpatient clinical visits for evaluation at
enrollment and week 8 of treatment. Figure 1 is a flow chart
for the selection, interventions, follow-up and outcomes.58 patie
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Figure 1 Flow chart of selection, interventions and outcomes.Assessment of outcomes
The number of apneas/hour will be measured at the base-
line and follow-up by type III portable polysomnography
(Somnocheck, Weinmann GmbH, Hamburg, Germany),
which was validated by us [10]. Average blood pressure
(two measurements using a validated automatic electronic
device) and ambulatory blood pressure (Spacelabs 90207,
Spacelabs, Redmond, WA) will be measured at the base-
line and follow-up.
Sleepiness will be measured using the Epworth somno-
lence scale at the baseline and follow-up. It records the
likelihood that someone will fall sleep during eight daily
activities (sitting and reading, watching television, sitting
in a public space, being passenger in a car for 1 hour,
lying down in the afternoon, sitting and talking to some-
one, sitting after a meal without alcohol and stopped in
a car for few minutes).
Adverse events will be investigated using open ques-
tions and a semi-structured questionnaire, with ques-
tions on general symptoms and the presumed adverse
effects of the drugs used in the trial. Standard laboratory
tests will be used to identify adverse events, such as
hypokalemia and elevated glucose levels. C-reactive pro-
tein levels will be determined as well.
Wash-out
Patients taking an antihypertensive drug will need to
stop it for 2 weeks prior to the study to be confirmed
for eligibility, to allow time for most of the effects of the
blood pressure drug to vanish [32].
Control of adherence
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For a mean of 20 apneas/hour at the baseline and a re-
duction of 7 apneas/hour, with a standard deviation of 9
apneas/hour, power of 80% and P alpha of 5%, 26 patients
will be required per group. The sample will be increased
by 10% to account for possible losses in follow-up, so that
58 patients need to be randomized.
Statistics
Differences between variables for the groups will be ana-
lyzed with chi-squared tests for categorical and Student’s t
tests for continuous variables. Confounding will be con-
trolled with logistic regression and multiple linear regres-
sion models.
Ethical approval
The project and the informed consent form were approved
by the ethics committee of the Hospital de Clínicas de
Porto Alegre, which is accredited by the Office of Human
Research Protections as an Institutional Review Board. All
participants will be asked to sign the informed consent
form prior to participation in the study.
Trial status
The trial is currently recruiting patients.
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